GOTHENBURG, Sweden , July 17, 2024 /PRNewswire/ --

Second quarter 

• Sales of SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK.
• Sales per region, in local currencies was -5% in APAC, +11% in EMEA and +5% in Americas.
• Sales growth per business area, in local currencies, was +3% in Consumables, +40% in Technologies and -7% in Genetics.
• Gross margin increased to 59.9% (55.8).
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 327 (293) million, giving an EBITDA margin of 34.7% (32.4).
• Operating cash flow increased to SEK 236 million (211).
• Net income increased to SEK 143 (106) million, giving earnings per share of SEK 1.06 (0.78).
• Vitrolife Group acquired the distribution activities of medical devices from EMB, our Iberian distributor.
• Vitrolife Group acquired eFertility (STB Zorg B.V.).

First half year

• Sales of SEK 1,782 (1,759) million, an increase of 2% in local currencies and 1% in SEK.
• Sales per region, in local currencies was +6% in APAC, +4% in EMEA and -4% in Americas.
• Sales per business area, in local currencies was +8% in Consumables, +23% in Technologies and -10% in Genetics.
• Gross margin increased to 58.6% (56.3).
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 600 (554) million, giving an EBITDA margin of 33.6% (31.5).
• Operating cash flow increased to SEK 434 million (372).
• Net income increased to SEK 258 (205) million, giving earnings per share of SEK 1.91 (1.52).             

Gothenburg, July 17, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-202408:00 CET.

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q2--2024--strong-technologies-growth-and-improved-margins,c4015708

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-interim-report-q2-2024-strong-technologies-growth-and-improved-margins-302199066.html

SOURCE Vitrolife AB (publ)